trial

Naltrexone for Antipsychotic-Induced Weight Gain

NCTId NCT01866098
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 144 (actual)
Sponsored by Yale University
Primary completion 2019-04-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
144 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2013-05
Primary completion
2019-04-07
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
Naltrexone

Sponsors

Yale UniversityLead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator

Investigators

1
Cenk Tek, MDPrincipal Investigator

Sites

1 total
New Haven, United States

Facts & assertions

4 sourced
Enrollment
144
Phase
NA
Primary Completion Date
2019-04-07
Status
COMPLETED
relationships
The graph out of here
drug
Naltrexone
drug
lead_sponsor
Yale University
company
collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
company
indication
Bipolar Disorder
indication
Schizophreniform Disorder
indication
Schizoaffective Disorder
indication
investigator
Cenk Tek, MD
person